Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.

Dranitsaris G, Beegle N, Kalberer T, Blau S, Cox D, Faria C.

J Oncol Pharm Pract. 2015 Jun;21(3):170-7. doi: 10.1177/1078155214525369.

PMID:
24620009
2.

Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.

Dranitsaris G, Gluck S, Faria C, Cox D, Rugo H.

Clin Ther. 2015 Jan 1;37(1):134-44. doi: 10.1016/j.clinthera.2014.10.023.

PMID:
25433768
3.

Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial.

Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G.

Breast Cancer Res Treat. 2015 Dec;154(3):509-20. doi: 10.1007/s10549-015-3633-7.

4.

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.

Cortes J, O'Shaughnessy J, Loesch D, Blum JL, Vahdat LT, Petrakova K, Chollet P, Manikas A, Diéras V, Delozier T, Vladimirov V, Cardoso F, Koh H, Bougnoux P, Dutcus CE, Seegobin S, Mir D, Meneses N, Wanders J, Twelves C; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators..

Lancet. 2011 Mar 12;377(9769):914-23. doi: 10.1016/S0140-6736(11)60070-6.

PMID:
21376385
5.

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J.

J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892.

6.

A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.

Pallis AG, Boukovinas I, Ardavanis A, Varthalitis I, Malamos N, Georgoulias V, Mavroudis D.

Ann Oncol. 2012 May;23(5):1164-9. doi: 10.1093/annonc/mdr405.

PMID:
21937705
7.

A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).

Gómez HL, Neciosup S, Tosello C, Mano M, Bines J, Ismael G, Santi PX, Pinczowski H, Nerón Y, Fanelli M, Fein L, Sampaio C, Lerzo G, Capó A, Zarba JJ, Blajman C, Varela MS, Martínez-Mesa J, Werutsky G, Barrios CH.

Clin Breast Cancer. 2016 Feb;16(1):38-44. doi: 10.1016/j.clbc.2015.10.005.

8.

A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.

Palmieri C, Alifrangis C, Shipway D, Tat T, Watson V, Mackie D, Emson M, Coombes RC.

Oncologist. 2012;17(11):1429-e47. doi: 10.1634/theoncologist.2012-0161.

9.

Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.

Cortes J, Vahdat L, Blum JL, Twelves C, Campone M, Roché H, Bachelot T, Awada A, Paridaens R, Goncalves A, Shuster DE, Wanders J, Fang F, Gurnani R, Richmond E, Cole PE, Ashworth S, Allison MA.

J Clin Oncol. 2010 Sep 1;28(25):3922-8. doi: 10.1200/JCO.2009.25.8467.

PMID:
20679609
10.

Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer.

Welt A, von Minckwitz G, Oberhoff C, Borquez D, Schleucher R, Loibl S, Harstrick A, Kaufmann M, Seeber S, Vanhoefer U.

Ann Oncol. 2005 Jan;16(1):64-9.

PMID:
15598940
11.

Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.

Martín M, Ruiz A, Muñoz M, Balil A, García-Mata J, Calvo L, Carrasco E, Mahillo E, Casado A, García-Saenz JA, Escudero MJ, Guillem V, Jara C, Ribelles N, Salas F, Soto C, Morales-Vasquez F, Rodríguez CA, Adrover E, Mel JR; Spanish Breast Cancer Research Group (GEICAM) trial..

Lancet Oncol. 2007 Mar;8(3):219-25.

PMID:
17329192
12.

Safety and tolerability of eribulin mesylate in patients with pretreated metastatic breast cancer.

Goodin S, Barbour S, Song J, Berrak E, Cox D.

Am J Health Syst Pharm. 2015 Dec 15;72(24):2150-6. doi: 10.2146/ajhp140773.

PMID:
26637514
13.

A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.

Lopes G, Glück S, Avancha K, Montero AJ.

Breast Cancer Res Treat. 2013 Jan;137(1):187-93. doi: 10.1007/s10549-012-2326-8.

PMID:
23143283
14.

Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.

Martella F, Bacci C, Giordano C, Montagnani F, Gelain E, Rabatti L, Fioretto L.

Future Oncol. 2015;11(15 Suppl):31-6. doi: 10.2217/fon.15.151. Erratum in: Future Oncol. 2016 Feb;12(3):427. Dosage error in article text.

PMID:
26235263
15.

Eribulin mesylate (Halaven) for breast cancer.

[No authors listed]

Med Lett Drugs Ther. 2011 Apr 18;53(1362):30-1.

PMID:
21502935
16.
17.

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.

Chan A, Conte PF, Petruzelka L, Tubiana-Mathieu N, Ganju V, Llombart A, Espie M, Majois F, Gil MG, Vaissiere N, Villanova G.

Anticancer Res. 2013 Jun;33(6):2657-64.

PMID:
23749924
18.

Gemcitabine and vinorelbine combination in patients with metastatic breast cancer.

Sanal SM, Gokmen E, Karabulut B, Sezgin C.

Breast J. 2002 May-Jun;8(3):171-6.

PMID:
12047474
19.

A phase I study of an all-oral combination of vinorelbine/capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes.

Kellokumpu-Lehtinen PL, Sunela K, Lehtinen I, Joensuu H, Sjöström-Mattson J; Finnish Breast Cancer Group..

Clin Breast Cancer. 2006 Dec;7(5):401-5.

PMID:
17239265
20.

Final results of an international retrospective observational study in patients with advanced breast cancer treated with oral vinorelbine-based chemotherapy.

Palomo AG, Glogowska I, Sommer H, Malamos N, Kilar E, Vega JM, Torrecillas L, Delozier T, Ettl J, Finek J.

Anticancer Res. 2012 Oct;32(10):4539-45.

PMID:
23060583
Items per page

Supplemental Content

Support Center